The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
Open accessAbstract
BACKGROUND: Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD). METHODS: Beginning in March 2015, we conducted a randomized, controlled trial of ZMapp plus the current standard of care as compared with the current standard of care alone in patients with EVD that was diagnosed in West Africa by polymerase-chain-reaction (PCR) assay. Eligible patients of any age were randomly assigned in a 1:1 ratio to receive either the current standard of care or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day). Patients were stratified according to baseline PCR cycle-threshold value for the virus (≤22 vs. >22) and country of enrollment. Oral favipiravir was part of the current standard of care in Guinea. The primary end point was mortality at 28 days. RESULTS: A total of 72 patients were enrolled at sites in Liberia, Sierra Leone, Guinea, and the United States. Of the 71 patients who could be evaluated, 21 died, representing an overall case fatality rate of 30%. Death occurred in 13 of 35 patients (37%) who received the current standard of care alone and in 8 of 36 patients (22%) who received the current standard of care plus ZMapp. The observed posterior probability that ZMapp plus the current standard of care was superior to the current standard of care alone was 91.2%, falling short of the prespecified threshold of 97.5%. Frequentist analyses yielded similar results (absolute difference in mortality with ZMapp, -15 percentage points; 95% confidence interval, -36 to 7). Baseline viral load was strongly predictive of both mortality and duration of hospitalization in all age groups. CONCLUSIONS: In this randomized, controlled trial of a putative therapeutic agent for EVD, although the estimated effect of ZMapp appeared to be beneficial, the result did not meet the prespecified statistical threshold for efficacy. (Funded by the National Institute of Allergy and Infectious Diseases and others; PREVAIL II ClinicalTrials.gov number, NCT02363322 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
Ebola haemorrhagic fever in Zaire
Otatume, S. (1996) · Journal of African Studies · doi:10.11619/africa1964.1996.49_95 · Cited by 474
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Collins, R., & MacMahon, S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03651-5 · Cited by 337
Hunt, L., Gupta-Wright, A., Simms, V., Tamba, F., Knott, V., Tamba, K., Heisenberg-Mansaray, S., Tamba, E., Sheriff, A., Conteh, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00144-9 · Cited by 204
Ebola in west Africa: from disease outbreak to humanitarian crisis
Piot, P., Muyembe, J., & Edmunds, W. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70956-9 · Cited by 134
Ebola viral load at diagnosis associates with patient outcome and outbreak evolution
Vega, M.-A. D. L., Caleo, G., Audet, J., Qiu, X., Kozak, R. A., Brooks, J., Kern, S. E., Wolz, A., Sprecher, A., Greig, J. E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83162 · Cited by 131
Fitzpatrick, G., VOGT, F. M., Gbabai, O., Decroo, T., Keane, M., Clerck, H. D., Grolla, A., Brechard, R., Stinson, K., & Herp, M. V. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv304 · Cited by 113
Blood kinetics of Ebola virus in survivors and nonsurvivors
Lanini, S., Portella, G., Vairo, F., Kobinger, G. P., Pesenti, A. M., Langer, M., Kabia, S., Brogiato, G., Amone, J., Castilletti, C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83111 · Cited by 98
Ebola virus (EBOV) infection: Therapeutic strategies
Clercq, E. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.11.008 · Cited by 87
Evaluating Ebola Therapies — The Case for RCTs
Cox, E. M., Borio, L. L., & Temple, R. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1414145 · Cited by 78
Li, J., Duan, H., Chen, H., Ji, Y., Zhang, X., Rong, Y.-H., Xu, Z., Sun, L., Zhang, J., Liu, L.-M., et al. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.10.021 · Cited by 73
Faye, O., Andronico, A., Faye, O., Salje, H., Boëlle, P., Magassouba, N., Bah, E. I., Koivogui, L., Diallo, B., Diallo, A. A., et al. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001908 · Cited by 62
Prognostic Indicators for Ebola Patient Survival
Crowe, S. J., Maenner, M. J., Kuah, S., Erickson, B. R., Coffee, M. P., Knust, B., Klena, J. D., Foday, J., Hertz, D., Hermans, V., et al. (2015) · Emerging infectious diseases · doi:10.3201/eid2202.151250 · Cited by 60
Lanini, S., Zumla, A. I., Ioannidis, J. P. A., Di, A., Krishna, S., Gostin, L. O., Girardi, E., Pletschette, M., Strada, G., Baritussio, A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70106-4 · Cited by 44
Statistical considerations for a trial of Ebola virus disease therapeutics
Proschan, M. A., Dodd, L. E., & Price, D. L. (2016) · Clinical Trials · doi:10.1177/1740774515620145 · Cited by 25
Trial design for evaluating novel treatments during an outbreak of an infectious disease
Whitehead, J., Olliaro, P., Lang, T. A., & Horby, P. (2016) · Clinical Trials · doi:10.1177/1740774515617740 · Cited by 19
Evaluating interventions for Ebola: The need for randomized trials
Fleming, T. R., & Ellenberg, S. S. (2016) · Clinical Trials · doi:10.1177/1740774515616944 · Cited by 17
Cited by
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
Metadata
- Authors
- The PREVAIL II Writing Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-13
- Volume
- 375
- Issue
- 15
- Pages
- 1448-1456
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2544612685
- Cited by
- 520
- References
- 21
- FWCI
- 56.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.